Clinical Trial Update: Serplulimab, Chidamide, and Rituximab Followed by Sequential R-CHOP for Newly Diagnosed Elderly MYC/BCL2 Double-Expressor DLBCL [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating serplulimab, chidamide, and rituximab followed by sequential R-CHOP in newly diagnosed elderly patients with MYC/BCL2 double-expre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Chidamide (chidamide)
• Rituximab (rituximab)
• Serplulimab (serplulimab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Newly Diagnosed MYC/BCL2 Double-expressor DLBCL | Phase 2 | Status: ACTIVE_NOT_RECRUITING